Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell death

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,601 result(s) found for: Cell death. Displaying page 1 of 131.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-005942-22 Sponsor Protocol Number: MK8669-021 Start Date*: 2009-01-15
    Sponsor Name:MERCK & CO., INC.
    Full Title: A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations.
    Medical condition: Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001436-10 Sponsor Protocol Number: INCB18424-266 Start Date*: 2015-02-26
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non–Small C...
    Medical condition: Nonsquamous NSCLC that is Stage IIIB, Stage IV, or recurrent
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DK (Prematurely Ended) ES (Prematurely Ended) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003657-26 Sponsor Protocol Number: ARD10248 Start Date*: 2012-01-16
    Sponsor Name:sanofi aventis recherche et développement
    Full Title: An open label non-randomized phase 2 study evaluating SAR3419, an anti-CD19 antibody – maytansine conjugate, administered as single agent by intravenous infusion to patients with relapsed or refrac...
    Medical condition: Diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002605-35 Sponsor Protocol Number: HO151 Start Date*: 2018-08-28
    Sponsor Name:HOVON Foundation
    Full Title: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma.
    Medical condition: Diffuse large B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002597-44 Sponsor Protocol Number: CFZ004 Start Date*: 2014-02-10
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer
    Medical condition: Untreated extensive stage small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003769-14 Sponsor Protocol Number: FIL_DLCL10 Start Date*: 2012-09-27
    Sponsor Name:Fondazione Italiana Linfomi ONLUS
    Full Title: R-CHOP-14 or R-CHOP-21 & consolidation PET–oriented radiotherapy (RT) in diffuse large B cell lymphoma (DLBCL) patients with low risk profile according to age-adjusted IPI (0 with bulky or 1)
    Medical condition: Patient with diffuse large B cell lymphoma (DLBCL) with low risk profile according to age-adjusted IPI (0 with bulky or 1)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000669-19 Sponsor Protocol Number: MO28107 Start Date*: 2012-07-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A COMPARATIVE, RANDOMIZED, PARALLEL-GROUP, MULTI-CENTRE, PHASE IIIB STUDY TO INVESTIGATE THE EFFICACY OF SUBCUTANEOUS (SC) RITUXIMAB VERSUS INTRAVENOUS (IV) RITUXIMAB BOTH IN COMBINATION WITH CHOP ...
    Medical condition: Adult patients aged 18-80 years with previously untreated CD20-positive diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) NL (Completed) GR (Completed) GB (Completed) IT (Completed) IE (Completed) FR (Completed) BE (Completed) BG (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024194-39 Sponsor Protocol Number: BO21005 Start Date*: 2011-04-15
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: ENSAYO DE FASE III, MULTICÉNTRICO, ABIERTO Y ALEATORIZADO PARA COMPARAR LA EFICACIA DE GA101 (RO5072759) EN COMBINACIÓN CON CHOP (G-CHOP) FRENTE A RITUXIMAB Y CHOP (R-CHOP) EN PACIENTES CON LINFOMA...
    Medical condition: PREVIOUSLY UNTREATED PATIENTS WITH CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) Pacientes CD20+ con linfoma difuso de celulas B grandes que no han sido previamente tratados
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012819 Diffuse large B-cell lymphomas HLT
    12.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) SK (Completed) CZ (Completed) HU (Completed) IT (Completed) DE (Completed) AT (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-007460-22 Sponsor Protocol Number: C-100-27 Start Date*: 2008-04-01
    Sponsor Name:Antigenics Inc.
    Full Title: International Survival Follow-up of Patients Enrolled In the Renal Cell Carcinoma Evaluation of Adjuvant Oncophage® Treatment in the Antigenics C-100-12 (Part I) Protocol (INSPIRE).
    Medical condition: Renal cell carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038395 Renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) AT (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004970-24 Sponsor Protocol Number: NHL-14 Start Date*: 2008-01-17
    Sponsor Name:AGMT - Arbeitsgemeinschaft Medikamentöse Tumortherapie Gemeinnützige GmbH
    Full Title: Multizentrische Studie über die Cardiotoxizität von R-CHOP (Rituximab, Cyclophosphamid, Doxorubicin, Vincristin und Prednisolon) v. R-COMP (Rituximab, Cyclophosphamid, liposomalem Doxorubicin, Vinc...
    Medical condition: Diffus großzelliges B-Zell Lymphom
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001421-24 Sponsor Protocol Number: FIL_R-BENDAFRAIL Start Date*: 2012-02-02
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Rituximab plus Bendamustine as front line treatment in frail elderly (≥70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana L...
    Medical condition: Patients with diffuse large B-cell non-Hodgkin’s lymphoma in frail elderly (≥70 years) patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002579-83 Sponsor Protocol Number: 54767414LUC2001 Start Date*: 2017-02-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic N...
    Medical condition: Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000498-40 Sponsor Protocol Number: CRAD001N2301 Start Date*: 2009-06-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching pla...
    Medical condition: Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) AT (Completed) IT (Completed) DE (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-017279-77 Sponsor Protocol Number: LNH2009-1B Start Date*: 2013-07-02
    Sponsor Name:GELARC
    Full Title: Randomized Phase III study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 y...
    Medical condition: Patient with Diffuse Large B cells with IPI=0 not previously treated
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004170-15 Sponsor Protocol Number: UCL/12/2015 Start Date*: 2016-11-17
    Sponsor Name:University College London
    Full Title: A multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine versus carboplatin/etoposide therapy alone in small cell lung cancer (SCLC)
    Medical condition: Small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-001491-20 Sponsor Protocol Number: STORM-2011 Start Date*: 2012-10-04
    Sponsor Name:Ruprecht-Karls University Heidelberg, Medical Faculty
    Full Title: A phase II trial to evaluate the safety, feasibility and efficacy of a salvage therapy consisting of the mTOR inhibitor Temsirolimus (Torisel™) added to the standard therapy of Rituximab and DHAP f...
    Medical condition: Diffuse large B-cell lymphoma with documented relapse or progression following at least one but a maximum of two prior treatments, aged older than 18 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004943 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006374-24 Sponsor Protocol Number: D5087C00001 Start Date*: 2022-07-08
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Ampli...
    Medical condition: EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002205-19 Sponsor Protocol Number: INCB50465-202 Start Date*: 2017-07-26
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Medical condition: Diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) PL (Completed) FR (Completed) ES (Temporarily Halted) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003795-49 Sponsor Protocol Number: IFCT-1603 Start Date*: 2016-12-16
    Sponsor Name:IFCT
    Full Title: A randomized multicenter, open label, controlled and non-comparative phase II study of anti–PDL1 ATEZOLIZUMAB (MPDL3280A) or chemotherapy as second-line therapy in patients with small cell lung can...
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041069 Small cell lung cancer limited stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023066-52 Sponsor Protocol Number: OMB114242 Start Date*: 2011-02-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multicenter study investigating the safety and efficacy of ofatumumab therapy versus physicians' choice in patients with bulky fludarabine refractory chronic lymphocytic leukaemia (CLL)
    Medical condition: Chronic lymphocytic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10068852 B-cell chronic lymphocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) HU (Completed) FR (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) SK (Completed) AT (Prematurely Ended) IT (Prematurely Ended) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:48:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA